Payment overview · 2025
General Payments
$146.46
7 reported records · 5 companies
Healthcare provider profile · identity verified
James Lee Owens, MD
Allopathic & Osteopathic Physicians|Family Medicine · JARVISBURG, NC · NPI 1962549345
Verified facts
What the public records show
CMS Open Payments records show James Lee Owens, MD received $146.46 in general payments during 2025 across 7 reported records.
Lilly USA, LLC accounted for 41.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Otezla.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OTEZLA as an associated drug or biological on 177267 records involving 48600 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Otezla by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 188 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $60.97 | 41.6% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $33.31 | 22.7% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.19 | 14.5% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $16.44 | 11.2% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $14.55 | 9.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $101.46 | 6 |
| Education | $45.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $21.19 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $16.67 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $16.64 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $16.64 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $16.44 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $16.44 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.97 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $14.55 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| OTEZLA otezla |
2025 | Otezla | 2024 | 41 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | OTEZLA open payments reported associated product |
CMS Open Payments — General Payments 177267 supporting records · 48600 recipient NPIs · example record 1226871616 |
Otezla · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
188 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 714 | 136 |
| Gabapentin | Gabapentin | 682 | 107 |
| Atorvastatin Calcium | Atorvastatin Calcium | 680 | 131 |
| Amlodipine Besylate | Amlodipine Besylate | 586 | 120 |
| Lisinopril | Lisinopril | 464 | 97 |
| Alprazolam | Alprazolam | 453 | 72 |
| Eliquis | Apixaban | 452 | 53 |
| Furosemide | Furosemide | 427 | 82 |
| Tramadol Hcl | Tramadol Hcl | 381 | 59 |
| Tamsulosin Hcl | Tamsulosin Hcl | 374 | 83 |
| Oxycodone Hcl | Oxycodone Hcl | 367 | 22 |
| Omeprazole | Omeprazole | 363 | 89 |
| Potassium Chloride | Potassium Chloride | 350 | 57 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 318 | 78 |
| Prednisone | Prednisone | 300 | 116 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 292 | 56 |
| Pantoprazole Sodium | Pantoprazole Sodium | 279 | 59 |
| Trazodone Hcl | Trazodone Hcl | 278 | 49 |
| Clopidogrel | Clopidogrel Bisulfate | 271 | 47 |
| Losartan Potassium | Losartan Potassium | 262 | 56 |
| Carvedilol | Carvedilol | 244 | 48 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 229 | 60 |
| Metformin Hcl | Metformin Hcl | 228 | 54 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 220 | 33 |
| Sertraline Hcl | Sertraline Hcl | 213 | 31 |
| Diclofenac Sodium | Diclofenac Sodium | 207 | 42 |
| Hydrochlorothiazide | Hydrochlorothiazide | 199 | 52 |
| Jardiance | Empagliflozin | 188 | 25 |
| Lorazepam | Lorazepam | 184 | 35 |
| Metoprolol Succinate | Metoprolol Succinate | 169 | 44 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 168 | 39 |
| Fluoxetine Hcl | Fluoxetine Hcl | 167 | 29 |
| Metoprolol Tartrate | Metoprolol Tartrate | 167 | 45 |
| Duloxetine Hcl | Duloxetine Hcl | 165 | 38 |
| Allopurinol | Allopurinol | 163 | 29 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 162 | 40 |
| Xarelto | Rivaroxaban | 161 | 17 |
| Glimepiride | Glimepiride | 149 | 30 |
| Escitalopram Oxalate | Escitalopram Oxalate | 141 | 25 |
| Citalopram Hbr | Citalopram Hydrobromide | 139 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 135 | 48 |
| Azithromycin | Azithromycin | 134 | 89 |
| Montelukast Sodium | Montelukast Sodium | 133 | 27 |
| Meloxicam | Meloxicam | 129 | 27 |
| Simvastatin | Simvastatin | 126 | 33 |
| Zolpidem Tartrate | Zolpidem Tartrate | 125 | 23 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 123 | 34 |
| Spironolactone | Spironolactone | 122 | 30 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 119 | 42 |
| Celecoxib | Celecoxib | 113 | 27 |
| Mirtazapine | Mirtazapine | 112 | 29 |
| Lactulose | Lactulose | 108 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 107 | 17 |
| Risperidone | Risperidone | 106 | 13 |
| Diazepam | Diazepam | 105 | 23 |
| Dicyclomine Hcl | Dicyclomine Hcl | 105 | 19 |
| Clonidine Hcl | Clonidine Hcl | 104 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 104 | 20 |
| Buspirone Hcl | Buspirone Hcl | 101 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 97 | 17 |
| Paroxetine Hcl | Paroxetine Hcl | 95 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 95 | 26 |
| Clonazepam | Clonazepam | 93 | 18 |
| Baclofen | Baclofen | 90 | 18 |
| Metformin Hcl Er | Metformin Hcl | 90 | 20 |
| Doxycycline Hyclate | Doxycycline Hyclate | 88 | 52 |
| Ibuprofen | Ibuprofen | 88 | 28 |
| Amiodarone Hcl | Amiodarone Hcl | 86 | 14 |
| Januvia | Sitagliptin Phosphate | 84 | suppressed |
| Ondansetron Odt | Ondansetron | 83 | 33 |
| Cephalexin | Cephalexin | 80 | 56 |
| Atenolol | Atenolol | 79 | 21 |
| Levetiracetam | Levetiracetam | 75 | suppressed |
| Bumetanide | Bumetanide | 72 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 72 | 18 |
| Finasteride | Finasteride | 70 | 20 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 68 | 13 |
| Savella | Milnacipran Hcl | 68 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 64 | 15 |
| Midodrine Hcl | Midodrine Hcl | 64 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 62 | 15 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 62 | 38 |
| Olanzapine | Olanzapine | 61 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 61 | 15 |
| Memantine Hcl | Memantine Hcl | 60 | 12 |
| Aripiprazole | Aripiprazole | 59 | 13 |
| Ozempic | Semaglutide | 59 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 59 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 59 | 15 |
| Symbicort | Budesonide/Formoterol Fumarate | 57 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 56 | 42 |
| Acyclovir | Acyclovir | 54 | suppressed |
| Ezetimibe | Ezetimibe | 54 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 54 | 16 |
| Topiramate | Topiramate | 54 | suppressed |
| Nystatin | Nystatin | 52 | 25 |
| Bupropion Hcl Sr | Bupropion Hcl | 50 | suppressed |
| Famotidine | Famotidine | 50 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 50 | 13 |
| Oxybutynin Chloride | Oxybutynin Chloride | 49 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 48 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 48 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 48 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 48 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 47 | 12 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 47 | 16 |
| Valsartan | Valsartan | 47 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 46 | 35 |
| Divalproex Sodium | Divalproex Sodium | 46 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 45 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 45 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 44 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 44 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 44 | suppressed |
| Pregabalin | Pregabalin | 44 | suppressed |
| Metolazone | Metolazone | 43 | 12 |
| Glipizide | Glipizide | 42 | suppressed |
| Xifaxan | Rifaximin | 42 | suppressed |
| Fluconazole | Fluconazole | 41 | 25 |
| Latanoprost | Latanoprost | 41 | suppressed |
| Otezla | Apremilast | 41 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 40 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 40 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 39 | 17 |
| Propranolol Hcl | Propranolol Hcl | 39 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 38 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 38 | 13 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 37 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 37 | suppressed |
| Mounjaro | Tirzepatide | 36 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 36 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 35 | suppressed |
| Dexamethasone | Dexamethasone | 33 | suppressed |
| Trulicity | Dulaglutide | 33 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 32 | 12 |
| Lamotrigine | Lamotrigine | 31 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 31 | 21 |
| Cyclobenzaprine Hcl Er | Cyclobenzaprine Hcl | 30 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 30 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 30 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 30 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 30 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 29 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 29 | suppressed |
| Estradiol | Estradiol | 28 | suppressed |
| Hydrocortisone | Hydrocortisone | 28 | suppressed |
| Levofloxacin | Levofloxacin | 28 | 20 |
| Linzess | Linaclotide | 28 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 27 | suppressed |
| Amoxicillin | Amoxicillin | 27 | 20 |
| Colchicine | Colchicine | 27 | suppressed |
| Eszopiclone | Eszopiclone | 27 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 27 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 27 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 26 | suppressed |
| Naproxen | Naproxen | 26 | suppressed |
| Bupropion Xl | Bupropion Hcl | 25 | suppressed |
| Entresto | Sacubitril/Valsartan | 25 | suppressed |
| Methocarbamol | Methocarbamol | 25 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 25 | 20 |
| Valacyclovir | Valacyclovir Hcl | 25 | 11 |
| Ibu | Ibuprofen | 24 | 11 |
| Insulin Lispro | Insulin Lispro | 24 | suppressed |
| Primidone | Primidone | 24 | suppressed |
| Digoxin | Digoxin | 23 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 23 | suppressed |
| Gemtesa | Vibegron | 23 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 22 | suppressed |
| Lovastatin | Lovastatin | 22 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 22 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 21 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 21 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 21 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 21 | suppressed |
| Synthroid | Levothyroxine Sodium | 21 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 21 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 21 | suppressed |
| Gemfibrozil | Gemfibrozil | 20 | suppressed |
| Methylprednisolone | Methylprednisolone | 20 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 20 | 20 |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 20 | suppressed |
| Sucralfate | Sucralfate | 20 | suppressed |
| Cefprozil | Cefprozil | 19 | 14 |
| Lansoprazole | Lansoprazole | 19 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 19 | suppressed |
| Mupirocin | Mupirocin | 19 | suppressed |
| Novolog Flexpen | Insulin Aspart | 19 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 19 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 18 | 18 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 18 | suppressed |
| Glipizide Er | Glipizide | 17 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 17 | suppressed |
| Klor-Con 10 | Potassium Chloride | 17 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 17 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 17 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 16 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 16 | suppressed |
| Methotrexate | Methotrexate Sodium | 16 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 16 | suppressed |
| Premarin | Estrogens, Conjugated | 16 | suppressed |
| Amantadine | Amantadine Hcl | 15 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 15 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 15 | suppressed |
| Myrbetriq | Mirabegron | 15 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 15 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | 11 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Ranolazine Er | Ranolazine | 14 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 14 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 13 | suppressed |
| Creon | Lipase/Protease/Amylase | 13 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Indomethacin | Indomethacin | 13 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Ivermectin | Ivermectin | 13 | suppressed |
| Rivastigmine | Rivastigmine | 13 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 12 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Trifluoperazine Hcl | Trifluoperazine Hcl | 12 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 11 | suppressed |
| Belsomra | Suvorexant | 11 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 11 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Fluorometholone | Fluorometholone | 11 | suppressed |
| Jantoven | Warfarin Sodium | 11 | suppressed |
| Methylprednisolone Acetate | Methylprednisolone Acetate | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $146.46 · 7 records | Lilly USA, LLC | JOURNAVX, MOUNJARO, OTEZLA, QULIPTA, REPATHA, UBRELVY, VOQUEZNA, VRAYLAR | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error